Related Experiment Video
Updated: Jul 15, 2025
14:39
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
31.9K
[Biologics in severe childhood asthma]
1Service de pneumologie et d'allergologie pédiatrique, CRCM, hôpital Robert-Debré, AP-HP, 48, boulevard Sérurier, 75019 Paris, France; Inserm 1018, Centre de recherche en épidémiologie et santé des populations, épidémiologie respiratoire intégrative, Villejuif, France.
Revue Des Maladies Respiratoires
|September 25, 2023
Summary
Severe pediatric asthma is a complex syndrome, not a single disease. Biologics offer new treatment avenues, with benralizumab and tezepelumab showing promise for future pediatric use.
Area of Science:
- Pediatric Pulmonology
- Immunology
- Biomarker Discovery
Context:
- Severe asthma in children is a heterogeneous syndrome with distinct phenotypes and pathophysiological pathways.
- Biomarkers such as IgE, FeNO, and eosinophil counts aid in phenotyping.
- Current approved biologics for severe pediatric asthma include omalizumab, mepolizumab, and dupilumab (from age 6), and tezepelumab (from age 12).
Purpose:
- To review the current landscape of severe pediatric asthma treatment.
- To highlight the role of biologics in managing severe asthma in children.
- To discuss emerging biologic therapies and future research directions.
Summary:
- Biologics represent a novel therapeutic strategy for severe asthma, targeting underlying pathophysiological mechanisms.
- Benralizumab and tezepelumab show particular promise, suggesting potential for pediatric application.
- Further research is needed to establish long-term efficacy and impact on disease progression in children.
Impact:
- Informs clinical practice regarding the use of biologics in severe pediatric asthma.
- Identifies key areas for future clinical trials in younger patient populations.
- Contributes to a better understanding of severe asthma as a syndrome rather than a single entity.
More Related Videos
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
326
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
326
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
289
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
289
01:19Antiasthma Drugs: Leukotriene Modifiers
338
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
338
01:20Asthma: Pathogenesis and Management
433
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
433
01:30Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
01:26Asthma-II: Pathophysiology and Classification
2.7K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.7K